AbbVie Inc (ABBV)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at AbbVie Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 250.90 $ — 83% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 7.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 28
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 14.09 | 13.91 – 14.54 | 67,579 | 40.9% | 25 |
| 12/31/2027 | 16.29 | 15.24 – 17.59 | 73,093 | 15.6% | 24 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.01 | -102.70 | 15,102 | 5.60 | -0.10 | 7,048 | 6,757 |
| 2025: Q1 | 0.73 | -6.00 | 13,343 | 8.40 | 9.60 | 1,635 | 1,400 |
| 2025: Q2 | 0.53 | -31.60 | 15,423 | 6.60 | 6.10 | 5,153 | 4,884 |
| 2025: Q3 | 0.10 | -88.10 | 15,776 | 9.10 | 1.20 | 7,024 | 7,528 |
| 2025: Q4 | 1.02 | – | 16,618 | 10.00 | 10.90 | 5,218 | 4,889 |
| 2026: Q1 | 0.39 | -45.70 | 15,002 | 12.40 | 4.70 | 3,829 | 3,564 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 25,638 | 9,340 | 5,953 | 3.65 | 7,041 | 4,636 | 66,099 |
| 2017 | 28,216 | 9,545 | 5,309 | 3.31 | 9,960 | 5,097 | 70,786 |
| 2018 | 32,753 | 6,383 | 5,687 | 3.68 | 13,427 | -8,446 | 59,352 |
| 2019 | 33,266 | 12,983 | 7,882 | 5.31 | 13,324 | -8,172 | 89,115 |
| 2020 | 45,804 | 11,363 | 4,616 | 2.76 | 17,588 | 13,097 | 150,565 |
| 2021 | 56,197 | 17,924 | 11,542 | 6.50 | 22,777 | 15,436 | 146,529 |
| 2022 | 58,054 | 18,117 | 11,836 | 6.66 | 24,943 | 17,287 | 138,805 |
| 2023 | 54,318 | 12,757 | 4,863 | 2.74 | 22,839 | 10,397 | 134,711 |
| 2024 | 56,334 | 9,137 | 4,278 | 2.41 | 18,806 | 3,364 | 135,161 |
| 2025 | 61,160 | 20,091 | 4,226 | 2.38 | 19,030 | -3,228 | 133,960 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
AbbVie Inc. ist ein forschungsbasiertes biopharmazeutisches Unternehmen, das weltweit Medikamente und Therapien erforscht, entwickelt, fertigt, kommerzialisiert und vertreibt.
| Employees | 57,000 |
|---|---|
| Headquarters | North Chicago, IL |
| Address | 1 North Waukegan Road, 60064-6400 North Chicago, United States |
| Phone | 847 932 7900 |
| Website | abbvie.com |
| IPO Date | 2. Jan 2013 |
| ISIN | US00287Y1091 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert A. Michael CPA | CEO & Chairman of the Board | 1970 |
| Scott T. Reents | Executive VP & CFO | 1968 |
| Roopal B. Thakkar M.D. | Executive VP of Research & Development and Chief Scientific Officer | 1972 |
| Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 1969 |
| Linda Ray | Senior VP & Chief Information Officer | – |
| Elizabeth Shea | Senior Vice President of Investor Relations | – |
| Perry C. Siatis | Executive VP, General Counsel & Secretary | 1975 |
| Demetris D. Crum | Executive VP & Chief Human Resources Officer | 1981 |
| Wulff-Erik von Borcke | Senior VP & President of Oncology | – |
| Nicholas J. Donoghoe M.D. | Executive VP and Chief Business & Strategy Officer | 1981 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.